Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPRFree Report) from a hold rating to a buy rating in a research note released on Saturday morning.

Several other analysts have also issued reports on the company. HC Wainwright reissued a buy rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. Bank of America downgraded Esperion Therapeutics from a neutral rating to an underperform rating and cut their price objective for the company from $2.90 to $2.50 in a research note on Thursday, June 20th. Finally, Needham & Company LLC decreased their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a buy rating on the stock in a research note on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Esperion Therapeutics has an average rating of Hold and an average price target of $8.17.

View Our Latest Stock Report on Esperion Therapeutics

Esperion Therapeutics Trading Up 1.5 %

Shares of NASDAQ ESPR opened at $2.07 on Friday. Esperion Therapeutics has a 12-month low of $0.70 and a 12-month high of $3.40. The firm has a market capitalization of $392.18 million, a price-to-earnings ratio of -2.09 and a beta of 1.00. The firm has a 50 day moving average of $1.83 and a 200 day moving average of $2.19.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last issued its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analysts’ expectations of $51.90 million. Sell-side analysts predict that Esperion Therapeutics will post -0.04 EPS for the current year.

Institutional Trading of Esperion Therapeutics

Several institutional investors have recently made changes to their positions in ESPR. Vanguard Group Inc. boosted its stake in Esperion Therapeutics by 71.8% in the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after purchasing an additional 3,688,796 shares during the period. Bellevue Group AG boosted its position in shares of Esperion Therapeutics by 136.5% during the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after acquiring an additional 5,739,800 shares during the last quarter. SG Americas Securities LLC purchased a new position in Esperion Therapeutics during the first quarter valued at $69,000. Marshall Wace LLP grew its stake in Esperion Therapeutics by 94.2% during the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after acquiring an additional 2,087,635 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Esperion Therapeutics by 3,278.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after acquiring an additional 555,382 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Read More

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.